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Background: A major challenge to the clinical utility of let-7 for hepatocellular carcinoma (HCC) therapy is the lack
of an effective carrier to target tumours. We confirmed the high transfection efficiency of cholesterol-conjugated
let-7a miRNA mimics (Chol-let-7a) in human HCC cells, as well as their high affinity for liver tissue in nude mice.
However, their antitumor efficacy via systemic delivery remains unknown.
Methods: We explored the effects of Chol-let-7a on HCC in vitro and in vivo. Cell viability and mobility, let-7a abundance
and the target ras genes was measured. Live-cell image and cell ultrastructure was observed. Antitumor efficacy in vivo
was analyzed by ultrasonography, hispatholgogy and transmission electronic microscopy in a preclinical model of HCC
orthotopic xenografts with systemic therapy.
Results: Chol-let-7a inhibited the viability and mobility of HCC cells. Chol-let-7a was primarily observed in the cytoplasm
and induced organelle changes, including autophagy. Mild changes were observed in the cells treated with negative
control miRNA. Chol-let-7a reached HCC orthotopic tumours, significantly inhibited tumour growth, and prevented local
invasion and metastasis. Compared to control tumours, Chol-let-7a-treated tumours showed more necrosis. Tumour cells
showed no significant atypia, and mitoses were very rare after systemic Chol-let-7a therapy. Furthermore, let-7a abundance
in orthotopic xenografts was coincident with a reduction in the expression of 3 human ras mRNAs and RAS proteins.
Conclusions: Chol-let-7a exerted significant antitumor effects by down-regulating all human ras genes at the
transcriptional and translational levels. Chol-let-7a inhibited cell proliferation, growth, and metastasis, and mainly
functioned in the cytoplasm. Chol-let-7a represents a potential useful modified molecule for systemic HCC therapy.Background
Hepatocellular carcinoma (HCC) is the fifth most common
cancer worldwide and the third most common cause of
cancer mortality and has high recurrence rates after sur-
gery. Chemotherapy and radiotherapy for HCC show lim-
ited efficacy and serious toxicity [1,2]. New therapeutic
strategies are urgently needed, particularly for the treatment
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unless otherwise stated.MicroRNAs (miRNAs) are endogenous non-coding
small RNAs that repress gene expression at the post-
transcriptional level by base pairing to the 3′-untrans-
lated region of target messenger RNAs, and they have
been identified as important mediators of carcinogenesis
and clinical prognosis [3-6]. The most recent findings
regarding the role of miRNAs in HCC confirmed that
they hold promise as new tools for diagnosis and therapy
[7-11]. A recent study in C. elegans reports that the let-7
family negatively regulates let-60/RAS, and also that the
let-60/RAS 3′-UTRs, including the 3′-UTRs of the
human ras genes, contain multiple let-7 complementary
sites (LCSs), which allow let-7 to regulate RAS proteinThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Liu et al. BMC Cancer 2014, 14:889 Page 2 of 13
http://www.biomedcentral.com/1471-2407/14/889expression [12]. Furthermore, let-7 has been reported to
inhibit tumour growth by down-regulating KRAS in
some cancers, such as pancreatic carcinoma and lung
cancer [13,14]. Analysis with a computational screen
showed that the human n-ras, k-ras, and h-ras mRNA
3′-UTRs have 9, 8, and 3 potential LCSs, respectively
[12]. Although ras proto-oncogenes produced by muta-
tions in codons 12, 13, and 61 do not play major roles in
hepatocellular carcinogenesis [15], abnormal activation
of the RAS pathway occurs in human HCC, and acti-
vated (GTP-bound) Pan-RAS, HRAS, KRAS, and NRAS
are significantly up-regulated in human hepatocarcino-
genesis [16,17]. Thus, we hypothesize that modulation of
let-7 expression and its target RAS is a promising strategy
for HCC treatment, because let-7 might suppress HCC
tumour growth by down-regulating all human ras genes.
Recently, antitumor effects of synthetic miRNA mimics
were confirmed in vitro and in vivo [18-20]. Hou et al.
showed that intratumoural administration of cholesterol-
conjugated PAK4 siRNA suppressed subcutaneous tumour
growth in the SMMC-LTNM model [21]. Trang and
colleagues [18] found that synthetic miR-34a and let-7
mimics caused lung tumour reduction in mice. However,
these mimics did not produced high miRNA levels in the
liver tissues. We confirmed the significantly higher trans-
fection efficiency of cholesterol-conjugated let-7a miRNA
mimics (Chol-let-7a) in human HCC cells in vitro. Given
the observed high affinity of Chol-let-7a for liver tissue in
nude mice, we hypothesize that Chol-let-7a may be an
ideal modified molecule for systemic HCC therapy.
In this study, we explored the effects of Chol-let-7a on
HCC tumour cells in vitro, as well as its antitumor effi-
cacy in an in vivo preclinical model of HCC orthotopic
xenografts, to evaluate its potential as a systemically
administered drug in the treatment of HCC. In addition,
we explored the effects of Chol-let-7a on ras gene
expression at the transcriptional and translational levels.
Methods
Materials and methods
Cell culture and mice
HepG2 and SMMC7721 cells were cultured in DMEM
(Invitrogen, Carlsbad, CA, USA) supplemented with
10% foetal bovine serum (Invitrogen) and pen/strep
(100 μg/mL). BALB/c nude (nu/nu) mice (6–7 weeks old,
20 ± 3 g) were purchased from the National Institutes for
Food and Drug Control (lot number: 11400500001092;
Beijing, China).
MTT cell proliferation assays
Cholesterol-conjugated let-7a mimics (Chol-let-7a) and
the negative control miRNA (Chol-miRCtrl) were pur-
chased from Ribobio (Guangzhou, China). Cells (5 × 103)
were cultured in 96-well flat-bottomed plates. After 24 h ofcell culture, cells were transfected with 50 nM Chol-let-7a
or Chol-miRCtrl according to manufacturer instructions.
Cells were cultured in 100 μL DMEM containing 10%
FBS and 20 μL MTS reagent powder (Promega, Madison,
WI, USA). Cells were harvested and seeded on 96-well
flat-bottomed plates, which were incubated at 37°C for
4 h. After incubation for 1, 2, 3, 4, or 5 days, the absorb-
ance at 550 nM was determined for each well.
Invasion and migration assay
Assays of invasion and migration were performed as
described in previous report [22]. For invasion assays,
5 × 104 cells in serum-free media were seeded into the
upper chambers of a 24-well BioCoat Matrigel invasion
chamber (Becton Dickinson Labware, Franklin Lakes,
NJ, USA) with an 8-μm pore polycarbonate membrane
coated with Matrigel. For migration assays, 5 × 104
cells were seeded into the upper chambers of a 24-well
BioCoat control insert (Becton Dickinson Labware,
Franklin Lakes, NJ, USA) with uncoated 8-μm pores in
serum-free media. Medium with 10% FBS was added to
the lower chambers as a chemoattractant. After 24 h of
incubation, cells remaining on the upper surface of the
membrane were removed with a cotton swab and cells
that invaded through the membrane filter were fixed
with 100% methanol, stained by hematoxylin and
eosin, and photographed by soft BioLife DP under a
microscope (Olympus BX40 with a DP70 digital camera,
Tokyo, Japan). The number of invading or migrating cells
was manually counted per high-power field for each
condition (eight fields on each membrane were ran-
domly selected).
Wounding assay
Cells were grown to confluence in 25 cm2 cell culture
flasks. Artificial wound tracks were created by scraping
confluent cell monolayers with a pipette tip. After
removal of the detached cells by gentle washing with
PBS, the cells were fed with fresh complete medium
and incubated to allow cells to migrate into the open
area. The ability of the cells to migrate into the wound
area was assessed at 24, 48, and 72 h after scratching by
comparing the wound tracks in micrographs of 3 ran-
domly selected wound areas.
Quantitative real-time PCR and reverse transcription PCR
Total miRNA from HCC cells or snap-frozen HepG2 xeno-
grafts was isolated using the mirVANA™ PARIS™ RNA iso-
lation kit (Applied Biosystems, Carlsbad, CA, USA). RNA
(10 ng) was reverse-transcribed with the miRNA Reverse
Transcription Kit (Applied Biosystems) and let-7a specific
primers (TaqMan miRNA assay, Applied Biosystems).
Total RNA was extracted from HCC cells or snap-
frozen HepG2 xenografts using the IllustraRNA spin
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Amersham Place, Little Chalfont, UK). cDNA was syn-
thesized using SuperScript TM III First-Strand Synthesis
SuperMix for quantitative real-time reverse transcription
PCR (qRT-PCR; Invitrogen Corporation, Carlsbad, CA,
USA) and primers specific for the 3 human ras genes
(TaqMan miRNA assay, Applied Biosystems).
Quantitative PCR was performed using RNU6 or GAPDH
as a housekeeping control with an ABI Prism 7500
Sequence Detection System (Perkin-Elmer Applied
Biosystems, Foster City, USA) and the Perkin-Elmer
Biosystems analysis software in a manner consistent
with the manufacturer’s instructions. Relative expres-
sion was calculated using the 2-ΔΔCTmethod [23].
Western blotting
HCC cells and tissues from snap-frozen HepG2 xenografts
were lysed using RIPA lysis buffer (Applygen Technologies,
Beijing, China). Proteins were quantified using a BCA pro-
tein kit (Applygen). Proteins (50 μg) were separated by
SDS-PAGE and transferred to an Immobilon-P membrane
(Millipore, Billerica, MA, USA). The membranes were
blocked in 5% non-fat milk and incubated with primary
antibodies. The membranes were washed in PBS-T (PBS
and 0.1% Tween-20) and incubated with a peroxidase-
conjugated secondary antibody (KPL, Gaithersburg, MD,
USA), followed by development with a chemiluminescent
substrate (Applygen). The Gel-Doc imaging system was
used to scan images on Kodak film. Antibodies for
KRAS, HRAS, and NRAS were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). GAPDH
and beta-actin (β-action) antibodies were obtained from
Proteintech (Chicago, IL, USA).
Transfection, live-cell imaging, and transmission electron
microscopy
HepG2 and SMMC771 cells were labelled with GFP.
Chol-let-7a and negative control mimics labelled with
Cy5 were purchased from Ribobio (Guangzhou, China).
The GFP-labelled cells (2–3 × 104) were seeded in 8-well
BD Falcon™ and BD BioCoat™ Culture Slides (Becton
Dickinson Labware, Franklin Lakes, NJ, USA). After 48 h,
cells were transfected with Cy5-labelled Chol-let-7a or the
negative control mimics (Chol-miRCtrl).
For live-cell imaging, cells were continuously observed
using a PerkinElmer UltraVIEW VoX-3D Live Cell
Imaging System (Shanghai, China) from 24 to 72 h
post-transfection. Digital images were produced using
Volocity Demo software (version 5.4, 32-bit). Co-
localization events were calculated using the Volocity
Demo software as described in the manufacturer’s
recommendations. The experiment was repeated 3
times and all samples for each individual experiment
were scanned at 5 different locations.For electron microscopy, cells were collected at 48 h
and 60 h after transfection and were fixed with 2.5%
glutaraldehyde for 30 min at room temperature, followed
by 1.5 h in 2% OsO4. Samples were stained and examined
with a transmission electron microscope (JEOL JEM 1010,
Tokyo, Japan), and digital images were obtained with
an Erlangshen ES1000W camera (Model 785, Gatan,
Warrendale, PA, USA).
In vivo experiments
All procedures were performed in accordance with the
Guide for the Care and Use of Laboratory Animals
(NIH publication nos. 80–23, revised 1996) and with
the experimental animal welfare ethics regulations of
China, with the approval of the Institution Animal Care
and Use Committee of Peking Union Medical College
Hospital. All animal experiments were performed at the
Centre for Experimental Animal Research (CEAR), Institute
of Basic Medical Sciences (IBMS), CAMS & PUMC.
Orthotopic xenograft model with nude mice and systemic
therapy with Chol-let-7a
HepG2 cells (2 × 106) were injected directly into the
livers of 20 nude mice. One week later, 18 mice with
successfully engrafted HepG2 orthotopic xenografts
were randomized into 3 groups of 6 animals each and
examined by ultrasonography in a double-blinded manner
(VisualSonics, Inc., Toronto, Ontario, Canada).
Two cohorts were treated with 5 nmol of Chol-let-7a
or the negative control mimic (Chol-miRCtrl) in 250 μL
saline buffer (Ribobio, Guangzhou, China) as suggested
by the instruction manual. Another cohort was treated
with saline buffer alone (blank). Systemic therapy was
administered via the tail vein every 3 days for 6 weeks.
Orthotopic tumour size in the liver and potential sec-
ondary metastases in the spleen were confirmed by
ultrasonography with a Vevo 2100 high-frequency ultra-
sound system (VisualSonics, Inc., Toronto, Ontario,
Canada) with measurements in 3 orthogonal axes (a, b,
and c). Tumour volumes were determined as V = (abc)/2
[24]. The presence of tumours was confirmed via 2-
dimensional vertical interfaces. Whole-animal imaging
was recorded using a Kodak FX Pro in vivo imaging sys-
tem. The xenograft growth curves of the 3 groups were
based on the mean volume of 6 samples weekly, and
inhibition was calculated based on the volume 5 weeks
(the tumours of the 2 control groups at week 6 were too
large for ultrasonography) after treatment as follows:
Inhibitory rate %ð Þ ¼ 1  mean volume of the treatment
group=mean volume blankð Þ  100
At the culmination of therapy, tumour tissues were
harvested and preserved in 10% neutral buffered
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were snap-frozen for qRT-PCR, western blotting, or
transmission electron microscopy.
Statistical analysis
Data are expressed as the mean ± SEM. All data analyses
were performed with SPSS 16.0 software (IBM, Inc.,
Armonk, NY, USA). Analysis of variance (ANOVA) and
Student’s t-test were used for statistical comparisons be-
tween groups. p <0.05 was considered to be statistically
significant.
Results
Chol-let-7a reduced HCC cell growth and viability in vitro
The growth curves of HepG2 and SMMC7721 cells
during the MTT assay are shown in Figure 1A and B,
respectively. After 5 days, Chol-let-7a decreased HepG2
and SMMC7721 viability by 37.7% and 36.6%, respectively,
in comparison with the parental cells (blank) (p <0.05).
No significant differences in growth were observed among
the 2 control HCC cell lines, the negative control miRNA
mimic (Chol-miRCtrl)-treated cells, and the parental cells
(p >0.05). These results verified that Chol-let-7a inhibited
HCC cell growth in vitro.
Chol-let-7a inhibited the migration and invasion of HCC
cells in vitro
We determined the effects of Chol-let-7a on HCC cell
migration and invasion, which are 2 key steps in tumour
metastasis. HepG2 and SMMC7721 cells were trans-
fected with Chol-let-7a or with Chol-miRCtrl as a nega-
tive miRNA control. The transfected Chol-let-7a and
Chol-miRCtrl cells and the parental cells were used in
the migration and invasion assay 48 h post-transfection.
A chamber-based cell migration assay revealed that
the number of Chol-let-7a-treated HCC cells that mi-
grated through the membrane was significantly lower
than the number of Chol-miRCtrl-treated cells (p <0.05)
or parental cells (blank) (p <0.05) that migrated through
the membrane (HepG2, 148.3 ± 7.02 (Chol-let-7a) vs.
203.0 ± 5.29 (Chol-miRCtrl) vs. 214.67 ± 11.67 (blank);
SMMC7721, 155.67 ± 6.66 (Chol-let-7a) vs. 218.33 ± 9.45
(Chol-miRCtrl) vs. 230.67 ± 7.02 (blank)) (Figure 1C).
There were no significant differences between the 2
control groups (p >0.05), indicating that Chol-let-7a
suppressed HCC cell migration.
We also used an in vitro wound healing assay to meas-
ure cell migration (data not shown). Healing speed was
slower and gaps were wider in the Chol-let-7a-treated
HepG2 and SMMC7721 cells at each time point (24,
48 h, and 72 h) in comparison with their respective
control groups. At 48 h, most gaps in the 2 control cell
groups were completely closed; whereas the gaps in the
Chol-let-7a-treated cells remained open. Consistentwith the results from the chamber-based cell migration
assay, these data indicated that Chol-let-7a inhibited
HCC cell migration.
Next, we evaluated the ability of HCC cells to pass
through the extracellular matrix (ECM) in a Boyden
chamber invasion assay. We found significantly fewer
invading cells in the Chol-let-7a-treated group in
comparison with the 2 control groups (Figure 1D)
(66.33 ± 4.73 (Chol-let-7a) vs. 91.33 ± 3.21 (Chol-miRCtrl)
vs. 97.00 ± 5.29 (blank); Chol-let-7a vs. the 2 control
groups, both p <0.05), and similar results were observed
with SMMC7721 cells (73.00 ± 5.29 (Chol-let-7a) vs.
91.33 ± 3.21 (Chol-miRCtrl) vs. 103.33 ± 4.73 (blank);
Chol-let-7a vs. the 2 control groups, both p <0.05).
Thus, it appears that Chol-let-7a affects cell migration
and invasion.
Up-regulated let-7a down-regulated ras/RAS expression in
HCC cells
We measured let-7a levels by quantitative real-time PCR
48 h after transfection with Chol-let-7a and Chol-miRCtrl.
Using miRNA-specific primers, let-7a up-regulation in
comparison with parental HCC cells and Chol-miRCtrl-
treated control cells was confirmed in Chol-let-7a-treated
cells (see Additional file 1A). Next, we analysed the
expression of let-7 target ras genes at the transcriptional
and translational levels 48 h after transfection. Western
blotting revealed a marked decrease in KRAS, HRAS,
and NRAS protein abundance in the Chol-let-7a-treated
HepG2 and SMMC7721 cells (see Additional file 1B).
Quantitative real-time PCR (qRT-PCR) was used to
measure k-ras, h-ras, and n-ras transcript abundance in
the Chol-let-7a-treated HCC cells, and these 3 ras
genes were found to be reduced by Chol-let-7a treat-
ment (see Additional file 1C). These results verified our
hypothesis that Chol-let-7a would inhibit the transcrip-
tion and translation of all 3 human ras genes in vitro.
Live-cell images
Images of live HCC cells were taken after treatment with
Chol-let-7a or the negative control miRNA (Chol-miRCtrl).
The parental cells served as blank controls that were visu-
ally inspected to evaluate potential off-target interactions
of Chol-miRCtrl. Living HepG2 and SMMC7721 cells
labelled by GFP were identified by green fluorescence.
Images taken at the various observation time points are
shown in Figure 2. The red fluorescence that indicated
Chol-let-7a and Chol-miRCtrl was primarily focused in the
cytoplasm (Figure 2). Through analysis of live images, we
found that most of the Chol-let-7a-treated cells lost GFP
fluorescence earlier than the 2 control groups (Figure 2).
Some Chol-let-7a-treated cells showed typical features of
apoptosis (Figure 2, Additional file 2). The numbers of
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Figure 1 Chol-let-7a inhibited HCC cell growth and cell viability in vitro. A,B: MTT assays show the effects of Chol-let-7a and Chol-miRCtrl on
the growth of HepG2 and SMMC7721 cells. The figure shows the growth curve of tumour cells from days 1–5. blank, parental cells; Chol-miRCtrl,
Chol-miRCtrl-transfected cells; Chol-let-7a, Chol-let-7a-transfected cells. C: A chamber-based cell migration assay showing that Chol-let-7a inhibits
the migration of HCC cells. HepG2: Chol-let-7a vs. Chol-miRCtrl vs. blank, 148.3 ± 7.02 vs. 203.0 ± 5.29 vs. 214.67 ± 11.67; T-test: Chol-let-7a vs.
Chol-miRCtrl, p = 0.001; Chol-let-7a vs. blank, p = 0.005; Chol-miRCtrl vs. blank, p = 0.207. SMMC7721: Chol-let-7a vs. Chol-miRCtrl vs. blank, 155.67 ±
6.66 vs. 218.33 ± 9.45 vs.230.67 ± 7.02; T-test: Chol-let-7a vs. Chol-miRCtrl, p = 0.021; Chol-let-7a vs. blank, p = 0.01; Chol-miRCtrl vs. blank, p = 0.066.
Magnification: 20× D: The inhibitory effect of Chol-let-7a on cell invasion ability in the Boyden chamber invasion assay. HepG2: Chol-let-7a vs.
Chol-miRCtrl vs. blank, 66.33 ± 4.73vs. 91.33 ± 3.21 vs. 97.00 ± 5.29; T-test: Chol-let-7a vs. Chol-miRCtrl, p = 0.005; Chol-let-7a vs. blank, p = 0.026;
Chol-miRCtrl vs. blank, p = 0.362. SMMC7721 cells: Chol-let-7a vs. Chol-miRCtrl vs. blank: 73.00 ± 5.29 vs. 91.33 ± 3.21 vs.103.33 ± 4.73. T-test: Chol-let-7a
vs. Chol-miRCtrl, p = 0.019; Chol-let-7a vs. blank, p =0.016; Chol-miRCtrl vs. blank, p = 0.408. Magnification: 20×.
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ively, at 24 h after transfection, and 5/50, 40/50, and 49/50,
respectively, at 39 h after transfection. Approximately 10/
50 cells had lost GFP fluorescence in the Chol-miRCtrl
group at 39 h after transfection. In addition, a few cells in
which cytoplasmic Chol-let-7a was observed did not
undergo cell death, and these cells subsequently lost their
red fluorescence. This observation shows that some Chol-
let-7a-treated cells did not die.A
Figure 2 Live-cell images. Live-cell images were taken from 24 h to 39 h
as blank controls. Laser confocal images of GFP-labelled live cells (green) w
appears as distinct red bodies. GFP-labelled living HepG2 or SMMC7721 ce
show more dead or apoptotic cells in Chol-let-7a-treated cells (yellow arrowContinuous observation of the images showed that
cell proliferation and mobility decreased in the Chol-
let-7a- and Chol-miRCtrl-treated cells. In addition,
images revealed that cell viability differed between the
2 control groups (Figure 2). There were no significant
differences in proliferation and cell mobility between
the 2 control groups immediately after Chol-miRCtrl
transfection. However, the Chol-miRCtrl-treated cells
exhibited poorer survival than the parental tumour cellsB
post-transfection. The parental cells with no treatment were observed
ere recorded in the 3 groups. Cy5-labelled Chol-let-7a or Chol-miRCtrl
lls appear green. Dead cells lose their green fluorescence. The images
s). A: HepG2 cells. B: SMMC7721 cells. Magnification: 160×.
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with GFP fluorescence were observed 72 h after treatment,
whereas the parental cells were still active with respect to
proliferation, growth, and mobility at this time point.
Ultrastructure features
We observed Chol-let-7a- and Chol-miRCtrl-treated cells
under transmission electronic microscopy (TEM) at 48 h
and 60 h post-transfection. Abnormal organelles were
observed in the cytoplasm of Chol-let-7a-treated cells
(Figure 3). Increased autophagocytic activity in HepG2
and SMMC7721 cells was observed 48 h after Chol-let-
7a treatment, as revealed by the presence of abundant
lysosomes and phagolysosomes exhibiting heteroly-
sosomes such as phagophores, multivesicular bodies
(MVBs), and multilamellar bodies (MLBs) in the cyto-
plasm (Figure 3), but only slight changes in nuclear
morphology were observed. Enlarged irregular mito-
chondria with disorganized mitochondrial crests andFigure 3 Organelle changes after Chol-let-7a therapy under transmissio
with Chol-let-7a or the negative control miRNA mimic (Chol-miRCtrl). Cells we
the cytoplasmic ultrastructure of Chol-let-7a-treated cells at 48 h post-transfec
multivesicular bodies (MVBs, yellow arrows), and multilamellar bodies (MLBs, o
mitochondria) and enlarged irregular mitochondria (mt) are shown with blue
bars are 0.5 μm or 0.2 μm.dilated rough endoplasmic reticulum (RER), which are
often accompanied by degranulation, were also clearly
observed in the Chol-let-7a-treated cells. Furthermore,
vacuolated organelles were found in individual cells.
Some changes observed in the Chol-let-7a-treated cells
were also found in Chol-miRCtrl-treated HCC cells (see
Additional file 3A); however, these effects were rela-
tively mild in the negative control cells.
Long-term treatment produced significant ultrastruc-
ture modifications. In the cytoplasm of Chol-let-7a-
treated cells, mitochondria, heterolysosomes, and RER
were vacuolated and showed irregular and unclear con-
tours and structures (see Additional file 3B), and apop-
totic and necrotic cells were clearly observed 60 h after
treatment. In the Chol-miRCtrl group, a few cells under-
went death. However, interestingly, cellular morphology
did not show characteristics associated with apoptotic
cells. Apoptotic nuclear changes, such as nuclear shrink-
age and nuclear fragmentation, were barely observedn electron microscopy. HepG2 and SMMC7721 cells were transfected
re collected at 48 h and 60 h and observed under TEM. The figure shows
tion. Also shown are heterolysosomes as phagophores (white arrows),
range arrows). Mitophagosomes (double-membrane-enclosed damaged
arrows. Red arrows indicate the dilated RER with degranulation. Scale
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rapid changes in cytoplasmic organelles, nuclear dam-
age was strikingly delayed after Chol-let-7a-treatment
(see Additional file 3C).Up-regulated let-7a down-regulated ras/RAS expression
after systemic delivery
To confirm that Chol-let-7a effectively carried let-7a to
target tumours in vivo, we measured let-7a abundanceA
C
B
Figure 4 Systemic Chol-let-7a therapy modulated ras/RAS abundance
orthotopic xenografts was examined by quantitative real-time PCR. Relative
threshold (CT) method (2 ΔΔct) with let-7a normalized to U6. The results sh
experiments, *p <0.05, **p <0.01 in comparison with controls. T-test: Chol-let-7
vs. blank, p = 0.128. B: RAS protein expression in xenografts examined by wes
xenografts by western blotting. Representative data are shown from 2 ex
quantification of target genes was calculated using the comparative cycle
The results shown represent the mean and standard error from 3 indepe
Analysis revealed deregulated expression of k-ras, h-ras, and n-ras mRNA.
blank, p = 0.002; Chol-miRCtrl vs. blank, p = 0.837); h-ras (Chol-let-7a vs. Ch
blank, p = 0.801); and k-ras (Chol-let-7a vs. Chol-miRCtrl, p = 0.041; Chol-letin HepG2 orthotopic xenografts by qRT-PCR after sys-
temic therapy. Using miRNA-specific primers, we found
significant increases in let-7a miRNA abundance in treated
xenografts (Figure 4A) (Chol-let-7a vs. Chol-miRCtrl,
p = 0.008; Chol-let-7a vs. blank, p = 0.013; Chol-miRCtrl
vs. blank, p =0.128). These results verified that Chol-let-7a
successfully reached tumour tissues.
We analysed the expression of RAS proteins by west-
ern blotting and observed marked decreases in KRAS,
HRAS, and NRAS abundance in Chol-let-7a-treatedin HCC orthotopic xenografts. A: Let-7a expression in HepG2
quantification of let-7a was calculated using the comparative cycle
own represent the mean and standard error from 3 independent
a vs. Chol-miRCtrl, p = 0.008; Chol-let-7a vs. blank, p = 0.013; Chol-miRCtrl
tern blotting. KRAS, HRAS, and NRAS protein expression was measured in
periments. C: qRT-PCR analysis of ras mRNA in xenografts. Relative
threshold (CT) method (2 ΔΔct) with genes normalized to GAPDH.
ndent experiments.*p <0.05, ** p <0.01 in comparison with controls.
T-test: n-ras (Chol-let-7a vs. Chol-miRCtrl, p = 0.002; Chol-let-7a vs.
ol-miRCtrl, p = 0.016; Chol-let-7a vs. blank, p = 0.033; Chol-miRCtrl vs.
-7a vs. blank, p = 0.005; Chol-miRCtrl vs. blank, p = 0.84).
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pression of k-ras, h-ras, and n-ras was also investigated
by qRT-PCR. The expression of n-ras was inhibited most
significantly by Chol-let-7a (p <0.01), and expression levels
of h-ras and k-ras (p <0.05) were also reduced (Figure 4C).
These results suggest that Chol-let-7a successfully carried
let-7a mimics into target HCC tumour cells and sup-
pressed all 3 human ras genes at the transcriptional and
translational levels, which were in accordance with our
in vitro results.Chol-let-7a inhibited growth and metastasis of HCC
orthotopic xenografts after systemic delivery
To study antitumor efficacy in vivo, we examined the
size of HepG2 orthotopic xenografts of different groups
by ultrasound weekly after cell transplantation. As
shown in Figure 5, the growth of orthotopic tumours
was significantly inhibited following Chol-let-7a therapy
(Figure 5A-C). One week after HepG2 cell transplant-
ation, the xenografts (Volume, mm3) of the Chol-let-7a
group (8.2854 ± 2.122593) were slightly larger than those
of the 2 control groups (Chol-miRCtrl, 7.8614 ± 1.69912;
blank, 7.0574 ± 1.340323), while the xenografts of the
Chol-let-7a-treated group (152.1528 ± 38.43266) were
significantly smaller than those of the 2 control groups
(Chol-miRCtrl, 424.3472 ± 60.10395; blank, 380.2284 ±
74.83116) at the culmination of therapy. The inhibitory
rates produced by Chol-let-7a and Chol-miRCtrl on
xenografts were 45.49% (p <0.01) and -7.13% (p >0.05),
respectively, in comparison with the blank control group
that was treated with saline buffer alone.
Beginning 2 weeks after Chol-let-7a treatment, in-
hibition of tumour metastasis was observed by ultra-
sonography. Metastases within the liver are shown in
Figure 5B. Local invasion and metastasis to the spleen
were inhibited in the Chol-let-7a-treated group (data
not shown).
Under light microscopy, small and large necrosis foci
were observed in tumour tissues from all 3 groups, but
more necrosis was observed in the Chol-let-7a-treated
xenografts, and necrosis was also observed in capillary-
rich areas. In contrast, significant necrosis was typically
observed in the central tumour area in the control
groups. These necrotic features were confirmed under
TEM (Figure 5D). In addition, Chol-let-7a-treated tumour
cells showed no significant atypia, and mitoses were very
rare per unit of measurement in most areas in comparison
with the control groups (Figure 5E). Immunohistochemi-
cal staining for Ki-67 and ultrastructure changes in HCC
cells in the orthotopic xenografts showed similar features
(data not shown). These results suggest that Chol-let-7a
inhibits tumour growth by promoting cell death and inhi-
biting cell proliferation.Discussion
We confirmed the significant antitumor efficacy of Chol-
let-7a on HCC, and in particular its significant effect on
HepG2 orthotopic xenografts after systemic delivery in a
preclinical animal model. Chol-let-7a effectively carried
let-7a mimics to target tumours in vivo and inhibited
tumour growth, metastasis within the liver, and local
invasion and metastasis to the spleen. Significant increases
in let-7a miRNA abundance were observed in Chol-let-
7a-treated xenografts. Moreover, let-7a abundance in
HepG2 orthotopic xenografts was coincident with a
reduction in the expression of 3 human ras mRNAs and
RAS proteins. These results suggest that Chol-let-7a
inhibits HCC cell growth by regulating all 3 human ras
genes at the transcriptional and translational levels.
We found some different features in the orthotopic
xenograft tissues after Chol-let-7a systemic therapy in
comparison with the 2 control groups. All tumour
tissues contained small and large necrosis foci, but more
necrosis was observed in the Chol-let-7a-treated xeno-
grafts, and necrosis was also observed in capillary-rich
areas. In contrast, significant necrosis was typically
observed in the central areas of tumours in the control
groups. The histopathological features of Chol-let-7a-
treated xenografts may have been induced by the type of
Chol-let-7a transportation used in this study. Tumour
cells in capillary-rich areas could be more susceptible
than other cells to systemically administered Chol-let-7a
molecules. In addition, well-differentiated tumour cells
with no significant atypia and only very rare mitoses
were observed after Chol-let-7a therapy. These results
suggest that Chol-let-7a inhibited tumour growth by
inhibiting cell proliferation and promoting cell death.
We confirmed that Chol-let-7a entered cells and func-
tioned primarily in the cytoplasm based on morphology
and ultrastructure analysis. This result was consistent
with the potential functional basis of let-7a, which
involves the inhibition of target ras genes at the tran-
scriptional and translational levels. In vitro, we observed
the effects of Chol-let-7a on HCC cells by living cell
image analysis and transmission electron microscopy.
Both results suggested that Chol-let-7a entered cells and
functioned primarily in the cytoplasm. The red fluores-
cence that indicated Chol-let-7a and Chol-miRCtrl was
primarily focused in the cytoplasm. TEM revealed that
Chol-let-7a damaged some cytoplasmic organelles, but
only slight changes in nuclear morphology were observed.
Cellular nuclear morphology did not show characteristics
associated with apoptotic cells even at 60 h after Chol-
let-7a therapy, when long-term treatment had produced
significant ultrastructure modifications in the cyto-
plasm. Apoptotic nuclear changes such as shrinkage
and fragmentation were barely observed in Chol-let-7a-
treated cells, including those in which mitochondria,
Figure 5 (See legend on next page.)
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Figure 5 Systemic Chol-let-7a therapy inhibited growth and metastasis of orthotopic HepG2 xenografts. A: Xenograft growth curve.
Representative xenografts from all groups are illustrated (N =6 mice per cohort). The Chol-let-7a (green), Chol-miRCtrl (red), and blank control
(blue) groups are shown. B: Macroscopic view of the HCC orthotopic tumour and metastasis within the liver of the treatment groups. C: Orthotopic
HepG2 xenografts examined by ultrasonography. Xenograft images were recorded 1, 3, and 5 weeks after HepG2 cells were transplanted. D: TEM of
HCC orthotopic tumours in vivo. Necrotic and tumour cells in HCC tissues are shown. Short red arrows indicate the microvasculature in orthotopic
tumours. Scale bars are 2 μm or 0.5 μm. E: H&E staining of orthotopic HCC tumour tissues. H&E staining was performed at the culmination of Chol-let-7a
therapy. Differentiation and mitoses (short yellow arrows) of HCC cells of the 3 treatment groups are shown; all were recorded beside necrotic areas.
Scale bars are 20 μm.
Liu et al. BMC Cancer 2014, 14:889 Page 11 of 13
http://www.biomedcentral.com/1471-2407/14/889heterolysosomes, and RER were vacuolated and showed
irregular and unclear contours and structures. In compari-
son with the rapid changes in cytoplasmic organelles,
nuclear damage was strikingly delayed after Chol-let-7a-
treatment. Autophagocytic activity was observed in Chol-
let-7a- treated cells. Therefore, we suggest that autophagy
may be an important mechanism through which Chol-let-
7a produces antitumor effects [25].
We previously examined the antitumor effect of Chol-
let-7a on HCC by using intratumoural administration in
a subcutaneous xenograft model. Results showed that
intratumoural administration of Chol-let-7a reduced
tumour growth; however, cell phenotype and morph-
ology in most areas of the subcutaneous xenografts
showed no such changes, and these areas showed ac-
tively growing cells with high rates of mitosis (data not
shown). Therefore, Chol-let-7a produces better inhibi-
tory effects when it is systemically administered. Because
of the high affinity of Chol-let-7a for liver tissue in nude
mice (data not shown) and the convenience of systemic
administration, Chol-let-7a represents a potential useful
modified molecule for systemic HCC therapy.
However, the delivery system may have off-target ef-
fects, as indicated by the differences observed between
the Chol-miRCtrl cells and the parental cells. Cell via-
bility differed between the 2 control groups. The Chol-
miRCtrl-treated cells exhibited poorer survival than the
parental tumour cells from 39 h after transfection, and
few living cells with GFP fluorescence were observed
72 h after treatment, whereas the parental cells were
still active with respect to proliferation, growth, and
mobility at this time point. This result suggests that
Chol-miRCtrl can reduce the viability of some cells. We
compared the effects of Chol-let-7a and Chol-miRCtrl
on HepG2 cells at 3 different doses. In comparison with
the 25 nM and 50 nM doses, 100 nM Chol-miRCtrl
slightly slowed cell growth 72 h after transfection (see
Additional file 4A), but there were no differences in
cell growth between the treatment groups at 48 h (see
Additional file 4B). These results suggest that dosage
and prolonged action time contribute to the off-target
effects of Chol-miRCtrl.
Ultrastructure features also differed between the 2
control groups. Some organelle changes observed in theChol-let-7a-treated cells were also found in the Chol-
miRCtrl-treated HCC cells under TEM. In addition, au-
tophagy was observed in some Chol-miRCtrl treated
tumour cells that under death, indicating that autopha-
gocytic activity could also be a potential factor induces
off-target effects. Given the observed high affinity of
Chol-let-7a for liver tissue in nude mice, we hypothesize
that Chol-let-7a may has potential off-target effects pri-
mary in liver tissue when it is administered systemically
as a therapeutic molecule. In future studies, we will in-
vestigate off-target effects of Chol-let-7a in preclinical
animal models.
Conclusions
We confirmed the significant antitumor efficacy of Chol-
let-7a on HCC, and in particular its significant effect on
HepG2 orthotopic xenografts after systemic delivery in a
preclinical animal model. Chol-let-7a effectively carried
let-7a to target tumours in vivo and inhibit tumour
growth by inhibiting cell proliferation and promoting cell
death. In addition, Chol-let-7a can inhibit HCC cell growth
by regulating all 3 human ras genes at the transcriptional
and translational levels. Moreover, we confirmed Chol-let-
7a entered cells and functioned primarily in the cytoplasm,
and autophagy may be an important mechanism through
which Chol-let-7a produces antitumor effects. Taken
together, Chol-let-7a represents a potential useful modified
molecule for systemic HCC therapy. However, further
studies of Chol-let-7a-produced off-target effects when
it is systemically administered are required.
Additional files
Additional file 1: Up-regulated let-7a down-regulated human ras/
RAS expression in HCC cells in vitro. A: Let-7a levels measured by
quantitative real-time PCR 48 h post-transfection of Chol-let-7a or Chol-miRCtrl.
Significant increases in let-7a levels in Chol-let-7a-treated HepG2 and
SMMC7721 cells are shown. T-test: HepG2: Chol-let-7a vs. Chol-miRCtrl,
p = 0.003; Chol-let-7a vs. blank, p = 0.003; Chol-miRCtrl vs. blank, p = 0.08.
SMMC7721: Chol-let-7a vs. Chol-miRCtrl, p = 0.001; Chol-let-7a vs. blank,
p = 0.001; Chol-miRCtrl vs. blank, p = 0.062. The results shown represent
the mean and standard error from 3 independent experiments.*p <0.05,
**p <0.01 in comparison with controls. (B) Expression of RAS proteins
examined by western blotting 48 h after transfection of Chol-let-7a or
Chol-miRCtrl. There was a marked decrease in KRAS, HRAS, and NRAS
protein abundance in Chol-let-7a-treated cells. (C) Deregulated expression
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http://www.biomedcentral.com/1471-2407/14/889of k-ras, h-ras, and n-ras mRNAs as determined by qRT-PCR 48 h after
transfection of Chol-let-7a. T-test for k-ras in HepG2: Chol-let-7a vs.
Chol-miRCtrl, p = 0.005; Chol-let-7a vs. blank, p = 0.002; Chol-miRCtrl vs.
blank, p = 0.286. T-test for k-ras in SMMC7721: Chol-let-7a vs. Chol-miRCtrl,
p =0.008; Chol-let-7a vs. blank, p = 0.007; Chol-miRCtrl vs. blank, p = 0.463.
T-test for h-ras in HepG2: Chol-let-7a vs. Chol-miRCtrl, p = 0.005; Chol-let-7a
vs. blank, p = 0.001; Chol-miRCtrl vs. blank, p = 0.081. T-test for h-ras in
SMMC7721: Chol-let-7a vs. Chol-miRCtrl, p = 0.032; Chol-let-7a vs. blank,
p = 0.023; Chol-miRCtrl vs. blank, p = 0.907. T-test for n-ras in HepG2:
Chol-let-7a vs. Chol-miRCtrl, p = 0.001; Chol-let-7a vs. blank, p = 0.004;
Chol-miRCtrl vs. blank, p = 0.755. T-test for n-ras in SMMC7721: Chol-let-7a vs.
Chol-miRCtrl, p = 0.001; Chol-let-7a vs. blank, p = 0.002; Chol-miRCtrl vs. blank,
p = 0.958. The results shown represent the mean and standard error from 3
independent experiments.*p <0.05, **p <0.01 in comparison with controls.
Additional file 2: Live cell images showing apoptosis and distribution
of Chol-let-7a and the negative control miRNA in HCC cells. The HCC
cells were labelled with GFP. The cholesterol-conjugated let-7a mimics
(Chol-let-7a), or negative control miRNA (Chol-miRCtrl) were labelled with
Cy5 fluorescence. Laser confocal images of GFP-labelled HepG2 and
SMMC7721 cells (green) treated with 50 nM Cy5-labelled Chol-let-7a or
Chol-miRCtrl are shown. The images are of HepG2 cells at 1 day after
injection. Cy5 fluorescence appears in the cytoplasm as distinct red
bodies surrounding the nucleus. Yellow arrow indicates an apoptotic
cell in Chol-let-7a-treated group.
Additional file 3: HCC cells after Chol-let-7a or Chol-miRCtrl
treatment observed by TEM. blank: Parental HCC cells; Chol-let-7a:
Chol-let-7a-treated HCC cells; Chol-miRCtrl: Chol-miRCtrl-treated HCC cells
A: HepG2 and SMMC7721 cells from the treatment groups at 48 h
post-transfection. B: Chol-let-7a-treated cells at 60 h post-transfection.
Vacuolated organelles with irregular and unclear contours and structures
are shown.C: HCC cells observed under TEM. Parental, Chol-let-7a- and
Chol-miRCtrl-treated HCC cells were observed under TEM at 48 h and
60 h after treatment. More dead and apoptotic cells were found in the
Chol-let-7a-treated cells, but some Chol-miRCtrl-treated cells showed
similar morphology.
Additional file 4: MTT assay of HepG2 cells transfected with
different doses of Chol-let-7a or Chol-miRCtrl. HepG2 cells were
transfected with 25 nM, 50 nM, or 100 nM of each treatment and the
absorbance at 550 nM was determined for each well at 48 h and 72 h
after transfection. A: MTT assay of HepG2 cells at 72h post-transfection
with different doses of each treatment. At 72 h, inhibition increased in a
dose-dependent manner in the Chol-let-7a-treated group. In addition,
cells transfected with 100 nM Chol-miRCtrl (short arrow) grew more
slowly than cells transfected with 25 nM and 50 nM Chol-miRCtrl. B: MTT
assay of HepG2 cells at 48 h post-transfection with different doses of
each treatment. At 48 h, HepG2 cells in the Chol-let-7a group were
inhibited. In the Chol-let-7a-treated group, inhibition increased as the
administered dose increased. No difference was observed between the
Chol-miRCtrl-treated groups (long arrow) and the parental cells (blank).
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